Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Designing a Secretory form of RTX-A as an Anticancer Toxin: An In Silico Approach

Author(s): Mortaza Taheri-Anganeh, Navid Nezafat, Saba Gharibi, Seyyed Hossein Khatami, Farzaneh Vahedi, Zahra Shabaninejad, Marzieh Asadi, Amir Savardashtaki, Ahmad Movahedpour* and Hassan Ghasemi*

Volume 18, Issue 4, 2024

Published on: 08 January, 2024

Page: [332 - 343] Pages: 12

DOI: 10.2174/0118722083267796231210060150

Price: $65

Abstract

Background: Cancer is a leading cause of death and a significant public health issue worldwide. Standard treatment methods such as chemotherapy, radiotherapy, and surgery are only sometimes effective. Therefore, new therapeutic approaches are needed for cancer treatment. Sea anemone actinoporins are pore-forming toxins (PFTs) with membranolytic activities. RTX-A is a type of PFT that interacts with membrane phospholipids, resulting in pore formation. The synthesis of recombinant proteins in a secretory form has several advantages, including protein solubility and easy purification. In this study, we aimed to discover suitable signal peptides for producing RTX-A in Bacillus subtilis in a secretory form.

Methods: Signal peptides were selected from the Signal Peptide Web Server. The probability and secretion pathways of the selected signal peptides were evaluated using the SignalP server. ProtParam and Protein-sol were used to predict the physico-chemical properties and solubility. AlgPred was used to predict the allergenicity of RTX-A linked to suitable signal peptides. Non-allergenic, stable, and soluble signal peptides fused to proteins were chosen, and their secondary and tertiary structures were predicted using GOR IV and I-TASSER, respectively. The PROCHECK server performed the validation of 3D structures.

Results: According to bioinformatics analysis, the fusion forms of OSMY_ECOLI and MALE_ECOLI linked to RTX-A were identified as suitable signal peptides. The final proteins with signal peptides were stable, soluble, and non-allergenic for the human body. Moreover, they had appropriate secondary and tertiary structures.

Conclusion: The signal above peptides appears ideal for rationalizing secretory and soluble RTX-A. Therefore, the signal peptides found in this study should be further investigated through experimental researches and patents.

« Previous Next »
Graphical Abstract

[1]
Kamath MA, Withers M. Human papilloma virus self-sampling performance in low- and middle-income countries. BMC Womens Health 2021; 21(1): 12.
[http://dx.doi.org/10.1186/s12905-020-01158-4] [PMID: 33407355]
[2]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[3]
Pastan IH, Pai LH, Brinkmann U, Fitzgerald DJ. Recombinant toxins: New therapeutic agents for cancer. Ann N Y Acad Sci 1995; 758(1): 345-54.
[http://dx.doi.org/10.1111/j.1749-6632.1995.tb24840.x] [PMID: 7625703]
[4]
Movahedpour A, Ahmadi N, Ghasemi Y, Savardashtaki A, Shabaninejad Z. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives. J Cell Biochem 2019; 120(10): 16316-29.
[http://dx.doi.org/10.1002/jcb.29053] [PMID: 31257636]
[5]
Shabaninejad Z, Yousefi F, Movahedpour A, et al. Electrochemical-based biosensors for microRNA detection: Nanotechnology comes into view. Anal Biochem 2019; 581: 113349.
[http://dx.doi.org/10.1016/j.ab.2019.113349] [PMID: 31254490]
[6]
Gomes A, Bhattacharjee P, Mishra R, et al. Anticancer potential of animal venoms and toxins. Indian J Exp Biol 2010; 48(2): 93-103.
[7]
Samavarchi TS, Gharibi S, Movahedpour A, et al. Design and evaluation of scFv-RTX-A as a novel immunotoxin for breast cancer treatment: An in silico approach. J Immunoassay Immunochem 2021; 42(1): 19-33.
[http://dx.doi.org/10.1080/15321819.2020.1812640] [PMID: 32845824]
[8]
Movahedpour A, Ahmadi K, Taheri-Anganeh M, Amiri A, Ahmadi N, Khatami SH, et al. Designing a humanized immunotoxin based on HER2 Specific scFv and DFF40 toxin against breast cancer: An in-silico study. Int J Pept Res Ther 2022; 28(5): 130.
[http://dx.doi.org/10.1007/s10989-022-10443-9]
[9]
Khirehgesh MR, Sharifi J, Akbari B, et al. Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR). J Drug Deliv Sci Technol 2021; 66: 102837.
[http://dx.doi.org/10.1016/j.jddst.2021.102837]
[10]
Hosseini HM, Amani J, Ataee MH, Mirhosseini SA, Mirnejad R, Rezaie E. Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity. Res Pharm Sci 2022; 17(4): 428-44.
[http://dx.doi.org/10.4103/1735-5362.350243] [PMID: 36034078]
[11]
Monastyrnaya M, Leychenko E, Isaeva M, et al. Actinoporins from the sea anemones, tropical Radianthus macrodactylus and northern Oulactis orientalis: Comparative analysis of structure–function relationships. Toxicon 2010; 56(8): 1299-314.
[http://dx.doi.org/10.1016/j.toxicon.2010.07.011] [PMID: 20692277]
[12]
Sonnen AF-P, Henneke P. Role of pore-forming toxins in neonatal sepsis. Clin Dev Immunol 2013; 2013: 608456.
[http://dx.doi.org/10.1155/2013/608456]
[13]
Alegre-Cebollada J. Oٌaderra M, Gavilanes J, del Pozo A. Sea anemone actinoporins: The transition from a folded soluble state to a functionally active membrane-bound oligomeric pore. Curr Protein Pept Sci 2007; 8(6): 558-72.
[http://dx.doi.org/10.2174/138920307783018686] [PMID: 18220843]
[14]
Bernheimer AW, Avigad LS. Properties of a toxin from the sea anemone Stoichacis helianthus, including specific binding to sphingomyelin. Proc Natl Acad Sci 1976; 73(2): 467-71.
[http://dx.doi.org/10.1073/pnas.73.2.467] [PMID: 1757]
[15]
Fedorov S, Dyshlovoy S, Monastyrnaya M, et al. The anticancer effects of actinoporin RTX-A from the sea anemone Heteractis crispa (Radianthus macrodactylus). Toxicon 2010; 55(4): 811-7.
[http://dx.doi.org/10.1016/j.toxicon.2009.11.016] [PMID: 19944712]
[16]
Ho CL, Ko JL, Lue HM, Lee CY, Ferlan I. Effects of equinatoxin on the guinea-pig atrium. Toxicon 1987; 25(6): 659-64.
[http://dx.doi.org/10.1016/0041-0101(87)90112-7] [PMID: 2888221]
[17]
Sket D, Drašlar K, Ferlan I, Lebez D. Equinatoxin, a lethal protein from Actinia equina—II. Pathophysiological action. Toxicon 1974; 12(1): 63-8.
[http://dx.doi.org/10.1016/0041-0101(74)90100-7] [PMID: 4150460]
[18]
Batista U, Sedmak B. The influence of cytolysin from the sea anemone Condylactis aurantiaca on normal and malignant mammalian cell lines. Eur J Cancer Clin Oncol 1985; 21(11): 1371.
[http://dx.doi.org/10.1016/0277-5379(85)90336-0]
[19]
Monastyrnaya MM, Zykova TA, Apalikova OV, Shwets TV, Kozlovskaya EP. Biologically active polypeptides from the tropical sea anemone Radianthus macrodactylus. Toxicon 2002; 40(8): 1197-217.
[http://dx.doi.org/10.1016/S0041-0101(02)00139-3] [PMID: 12165324]
[20]
Turk T. Cytolytic toxins from sea anemones. J Toxicol Toxin Rev 1991; 10(3): 223-62.
[http://dx.doi.org/10.3109/15569549109053857]
[21]
Avila AD, Mateo Acosta CD, Lage A. A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin. Int J Cancer 1989; 43(5): 926-9.
[http://dx.doi.org/10.1002/ijc.2910430533] [PMID: 2785509]
[22]
Pederzolli C, Belmonte G, Serra MD, Macek P, Menestrina G. Biochemical and cytotoxic properties of conjugates of transferrin with equinatoxin II, a cytolysin from a sea anemone. Bioconjug Chem 1995; 6(2): 166-73.
[http://dx.doi.org/10.1021/bc00032a003] [PMID: 7599260]
[23]
Tejuca M, Anderluh G, Maček P, et al. Antiparasite activity of sea-anemone cytolysins on Giardia duodenalis and specific targeting withanti-Giardia antibodies. Int J Parasitol 1999; 29(3): 489-98.
[http://dx.doi.org/10.1016/S0020-7519(98)00220-3] [PMID: 10333333]
[24]
Xiao Y, Luo X, Kuang F, et al. Synthesis and characterization of huwentoxin-IV, a neurotoxin inhibiting central neuronal sodium channels. Toxicon 2008; 51(2): 230-9.
[http://dx.doi.org/10.1016/j.toxicon.2007.09.008] [PMID: 18054060]
[25]
Najafi M, Eteraf-Oskouei T, Akbarzadeh-Atashkhosrow A, Maghsudi M. Effects of salbutamol on the inflammatory parameters and angiogenesis in the rat air pouch model of inflammation. Res Pharm Sci 2017; 12(5): 364-72.
[http://dx.doi.org/10.4103/1735-5362.213981] [PMID: 28974974]
[26]
Khatami SH, Taheri-Anganeh M, Movahedpour A, et al. Serodiagnosis of human cystic echinococcosis based on recombinant antigens B8/1 and B8/2 of Echinococcus granulosus. J Immunoassay Immunochem 2020; 41(6): 1010-20.
[http://dx.doi.org/10.1080/15321819.2020.1807359] [PMID: 32795213]
[27]
Huang CJ, Lin H, Yang X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 2012; 39(3): 383-99.
[http://dx.doi.org/10.1007/s10295-011-1082-9] [PMID: 22252444]
[28]
Savardashtaki A, Sharifi Z, Hamzehlou S, Farajollahi MM. Analysis of immumoreactivity of heterologously expressed non-structural protein 4B (NS4B) from hepatitis C virus (HCV) genotype 1a. Iran J Biotechnol 2015; 13(4): 32-7.
[http://dx.doi.org/10.15171/ijb.1321] [PMID: 28959307]
[29]
Chae YK, Kim SH, Markley JL. Relationship between recombinant protein expression and host metabolome as determined by two-dimensional NMR spectroscopy. PLoS One 2017; 12(5): e0177233.
[http://dx.doi.org/10.1371/journal.pone.0177233] [PMID: 28486539]
[30]
Baneyx F. Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 1999; 10(5): 411-21.
[http://dx.doi.org/10.1016/S0958-1669(99)00003-8] [PMID: 10508629]
[31]
Sørensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005; 115(2): 113-28.
[http://dx.doi.org/10.1016/j.jbiotec.2004.08.004] [PMID: 15607230]
[32]
Kaur J, Kumar A, Kaur J. Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. Int J Biol Macromol 2018; 106: 803-22.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.08.080] [PMID: 28830778]
[33]
Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000; 66(4): 1572-9.
[http://dx.doi.org/10.1128/AEM.66.4.1572-1579.2000] [PMID: 10742244]
[34]
Choi JH, Lee SY. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 2004; 64(5): 625-35.
[http://dx.doi.org/10.1007/s00253-004-1559-9] [PMID: 14966662]
[35]
Parsell DA, Sauer RT. The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli. J Biol Chem 1989; 264(13): 7590-5.
[http://dx.doi.org/10.1016/S0021-9258(18)83275-6] [PMID: 2651442]
[36]
a) Khatami SH, Taheri-Anganeh M, Arianfar F, et al. Analyzing signal peptides for secretory production of recombinant diagnostic antigen B8/1 from Echinococcus granulosus: An in silico approach. Mol Biol Res Commun 2020; 9(1): 1-10.;
b) Song Z. Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics. Patent US10066019B2, 2018.
[PMID: 32582787]
[37]
Owji H, Nezafat N, Negahdaripour M, Hajiebrahimi A, Ghasemi Y. A comprehensive review of signal peptides: Structure, roles, and applications. Eur J Cell Biol 2018; 97(6): 422-41.
[http://dx.doi.org/10.1016/j.ejcb.2018.06.003] [PMID: 29958716]
[38]
Tuteja R. Type I signal peptidase: An overview. Arch Biochem Biophys 2005; 441(2): 107-11.
[http://dx.doi.org/10.1016/j.abb.2005.07.013] [PMID: 16126156]
[39]
Zimmermann R, Eyrisch S, Ahmad M, Helms V. Protein translocation across the ER membrane. Biochim Biophys Acta Biomembr 2011; 1808(3): 912-24.
[http://dx.doi.org/10.1016/j.bbamem.2010.06.015]
[40]
Tehrani SS, Goodarzi G, Naghizadeh M, et al. Suitable signal peptides for secretory production of recombinant granulocyte colony stimulating factor in Escherichia coli. Recent Pat Biotechnol 2020; 14(4): 269-82.
[http://dx.doi.org/10.2174/1872208314999200730115018] [PMID: 32838727]
[41]
Chang CCH, Song J, Tey BT, Ramanan RN. Bioinformatics approaches for improved recombinant protein production in Escherichia coli: Protein solubility prediction. Brief Bioinform 2014; 15(6): 953-62.
[http://dx.doi.org/10.1093/bib/bbt057] [PMID: 23926206]
[42]
de Souza GA, Leversen NA, Målen H, Wiker HG. Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway. J Proteomics 2011; 75(2): 502-10.
[http://dx.doi.org/10.1016/j.jprot.2011.08.016] [PMID: 21920479]
[43]
Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng Des Sel 1997; 10(1): 1-6.
[http://dx.doi.org/10.1093/protein/10.1.1] [PMID: 9051728]
[44]
Taheri-Anganeh M, Amiri A, Movahedpour A, et al. In silico evaluation of PLAC1-fliC as a chimeric vaccine against breast cancer. Iran Biomed J 2020; 24(3): 173-82.
[http://dx.doi.org/10.29252/ibj.24.3.173] [PMID: 31952435]
[45]
Sakurai T, Kataoka K. Basic and applied features of multicopper oxidases, CueO, bilirubin oxidase, and laccase. Chem Rec 2007; 7(4): 220-9.
[http://dx.doi.org/10.1002/tcr.20125] [PMID: 17663447]
[46]
Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157(1): 105-32.
[http://dx.doi.org/10.1016/0022-2836(82)90515-0] [PMID: 7108955]
[47]
Freudl R. Signal peptides for recombinant protein secretion in bacterial expression systems. Microb Cell Fact 2018; 17(1): 52.
[http://dx.doi.org/10.1186/s12934-018-0901-3] [PMID: 29598818]
[48]
Nielsen H, Kihara D. Protein sorting prediction. Methods Mol Biol 2017; 1615: 23-57.
[http://dx.doi.org/10.1007/978-1-4939-7033-9_2]
[49]
Linhartová I, Bumba L, Mašín J, et al. RTX proteins: A highly diverse family secreted by a common mechanism. FEMS Microbiol Rev 2010; 34(6): 1076-112.
[http://dx.doi.org/10.1111/j.1574-6976.2010.00231.x] [PMID: 20528947]
[50]
Shur O, Dooley K, Blenner M, Baltimore M, Banta S. A designed, phase changing RTX-based peptide for efficient bioseparations. Biotechniques 2013; 54(4) 197-206, 200, 202, 204, 206.
[http://dx.doi.org/10.2144/000114010] [PMID: 23581466]
[51]
Guruprasad K, Reddy BVB, Pandit MW. Correlation between stability of a protein and its dipeptide composition: A novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng Des Sel 1990; 4(2): 155-61.
[http://dx.doi.org/10.1093/protein/4.2.155] [PMID: 2075190]
[52]
Abrusán G, Marsh JA. Alpha helices are more robust to mutations than beta strands. PLOS Comput Biol 2016; 12(12): e1005242.
[http://dx.doi.org/10.1371/journal.pcbi.1005242] [PMID: 27935949]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy